Sarpogrelate Hydrochloride, a Selective 5-HT2A Antagonist, Augments Autologous Bone-Marrow Mononuclear Cell Implantation-induced Improvement in Endothelium-Dependent Vasodilation in Patients with Critical Limb Ischemia. Journal of cardiovascular pharmacology [J Cardiovasc Pharmacol] Journal article | | Title | Sarpogrelate Hydrochloride, a Selective 5-HT2A Antagonist, Augments Autologous Bone-Marrow Mononuclear Cell Implantation-induced Improvement in Endothelium-Dependent Vasodilation in Patients with Critical Limb Ischemia. | | Author(s) | Higashi Y, Miyazaki M, Goto C, Sanada H, Sueda T, Chayama K | | Institution | Department of Cardiovascular Physiology and Medicine (C.G., Y.H.), Department of Medicine and Molecular Science (K.C.), Department of Surgery (M.M, H.S. and T.S.), Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan. | | Source | J Cardiovasc Pharmacol 2009 Oct 9. | | Abstract | BACKGROUND:: The purpose of this study was to determine the effect of a combination of bone-marrow mononuclear cell (BM-MNC) implantation and sarpogrelate, a selective 5-HT2A antagonist, on endothelial function in patients with critical limb ischemia (CLI).
METHODS:: We evaluated the leg blood flow (LBF) responses to acetylcholine and sodium nitroprusside (SNP) before and after BM-MNC implantation in 16 patients with CLI. We divided CLI patients into two groups: those co-treated with sarpogrelate orally for 12 weeks (sarpogrelate group, n=8) and those who remained on conventional therapy (control group, n=8). LBF was measured by strain-gauge plethysmography.
RESULTS:: BM-MNC implantation improved ankle-brachial pressure index, transcutanous oxygen pressure, and pain-free walking time. There was no significant difference in these parameters between the two groups. Before BM-MNC implantation, LBF responses to acetylcholine were similar in the sarpogrelate group and control group. Twelve weeks of BM-MNC implantation enhanced LBF responses to acetylcholine in the sarpogrelate and control groups. After 12 weeks of BM-MNC implantation, LBF response to acetylcholine was significantly greater in the sarpogrelate group than in the control group. BM-MNC implantation did not alter the LBF responses to SNP in either group.
CONCLUSION:: These findings suggest that BM-MNC implantation improved not only limb ischemic symptoms but also endothelium-dependent vasodilation in patients with CLI. A combination of BM-MNC implantation and sarpogrelate had a more beneficial effect on vascular function in these patients. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19834330 |
|
|
| |
Advertise on this site.
| | |
|
